

**DESCRIPTION**

<b>Source</b>	Mouse myeloma cell line, NS0-derived human IL-12 R beta 2 protein			
	Human IL-12 R $\beta$ 2 (Lys24-Asn622) Accession # Q99665-1	IEGRMD	Human IgG <sub>1</sub> (Pro100-Lys330)	6-His tag
	N-terminus		C-terminus	
<b>N-terminal Sequence</b>	Lys24			
<b>Analysis</b>				
<b>Structure / Form</b>	Disulfide-linked homodimer			
<b>Predicted Molecular Mass</b>	95 kDa			

**SPECIFICATIONS**

<b>SDS-PAGE</b>	112-133 kDa, reducing conditions
<b>Activity</b>	Measured by its binding ability in a functional ELISA. When Recombinant Human IL-12 (Catalog # 219-IL) is immobilized at 0.5 $\mu$ g/mL, 100 $\mu$ L/well, the concentration of Recombinant Human IL-12 R $\beta$ 2 Fc that produces 50% of the optimal binding response is 0.015-0.09 $\mu$ g/mL.
<b>Endotoxin Level</b>	<0.10 EU per 1 $\mu$ g of the protein by the LAL method.
<b>Purity</b>	>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
<b>Formulation</b>	Lyophilized from a 0.2 $\mu$ m filtered solution in PBS with Trehalose. See Certificate of Analysis for details.

**PREPARATION AND STORAGE**

<b>Reconstitution</b>	Reconstitute at 250 $\mu$ g/mL in PBS.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
<b>Stability &amp; Storage</b>	<p><b>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</b></p> <ul style="list-style-type: none"> <li>• 12 months from date of receipt, -20 to -70 <math>^{\circ}</math>C as supplied.</li> <li>• 1 month, 2 to 8 <math>^{\circ}</math>C under sterile conditions after reconstitution.</li> <li>• 3 months, -20 to -70 <math>^{\circ}</math>C under sterile conditions after reconstitution.</li> </ul>

**DATA**

**Binding Activity**

When Recombinant Human IL-12 (Catalog # 219-IL) is immobilized at 0.5  $\mu$ g/mL, Recombinant Human IL-12 R beta 2 Fc Chimera (Catalog # 1959-B2B) binds with an ED<sub>50</sub> of 0.015-0.09  $\mu$ g/mL.

**SDS-PAGE**

1  $\mu$ g/lane of Recombinant Human IL-12 R $\beta$ 2 was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by silverstaining, showing bands at 112-133 kDa and 220-260 kDa, respectively.

**BACKGROUND**

The high-affinity IL-12 receptor complex includes the 100-kDa IL-12 Receptor β1 (IL-12 Rβ1) and the 130-kDa IL-12 Receptor β2 (IL-12 Rβ2) subunits, both type I transmembrane proteins within the cytokine receptor superfamily (1, 2). Its ligand, IL-12, is a disulfide-linked dimer of 35-kDa (IL-12α p35) and 40-kDa (IL-12β p40) subunits. IL-12 Rβ2 binds IL-12α and signals through Jak2, while IL-12 Rβ1 binds IL-12β and signals through Tyk2 (3). IL-12 Rβ1 is also a subunit of the IL-23 receptor complex (3). The 862 amino acid (aa) human IL-12 Rβ2 includes a 23 aa signal peptide, a 599 aa extracellular domain (ECD) with five fibronectin type III (Fn III) domains, 8 potential N-glycosylation sites, and a WSXWS motif, a 21 aa transmembrane domain and a 219 aa cytoplasmic region with a Box 1 motif and a tyrosine phosphorylation site that both mediate intracellular signaling (3). Human IL-12 Rβ2 ECD shares 69%, 67%, 79%, 81% and 82% aa sequence identity with mouse, rat, canine, porcine and bovine IL-12 Rβ2, respectively. Human and mouse IL-12 Rβ2 do not bind cross-species IL-12 (2). A human alternatively spliced 659 aa form contains a shortened, altered cytoplasmic sequence (4). Unlike IL-12 Rβ1, which is constitutive in T cells, NK cells and B cells, IL-12 Rβ2 expression is more limited (2). IL-12 Rβ2 is expressed following STAT1 activation by IFN-γ, IL-27 and/or T cell receptor stimulation of naïve T cells, allowing IL-12 to promote Th1, but not Th2, differentiation (5-7). Among B cells, surface expression is limited to naïve germinal center and memory B cells, and myeloma cells (2). Deletion of mouse IL-12 Rβ2 causes systemic overexpression of IL-6, accelerated maturation of thymocytes, deficient regulatory T cell maturation and function, and reduced splenic T cell apoptosis (2, 8-10). These mice are susceptible to autoimmune diseases such as experimental autoimmune encephalitis and spontaneous B cell malignancies (2, 8-10). In humans, polymorphism of the IL-12 Rβ2 gene is associated with systemic sclerosis (11).

**References:**

1. Presky, D.H. *et al.* (1996) *Proc. Natl. Acad. Sci. USA* **93**:14002.
2. Pistoia, V. *et al.* (2009) *J. Clin. Oncol.* **27**:4809.
3. Zou, J. *et al.* (1997) *J. Biol. Chem.* **272**:6073.
4. SwissProt accession # Q99665
5. Rogge, L. *et al.* (1997) *J. Exp. Med.* **185**:825.
6. Becskei, A. and M.J. Grusby (2007) *FEBS Lett.* **581**:5199.
7. Szabo, S.J. *et al.* (1997) *J. Exp. Med.* **185**:817.
8. Zhao, Z. *et al.* (2008) *J. Immunol.* **181**:3870.
9. Gran, B. *et al.* (2010) *Exp. Mol. Pathol.* **89**:126.
10. Airoidi, I. *et al.* (2005) *Blood* **106**:3846.
11. Bossini-Castillo, L. *et al.* (2012) *Hum. Mol. Genet.* **21**: 926